The Research of the application of a new Urinary Biomarker PCA-M of Prostate Cancer (PSA from 4 to 20 ng/ml)

Background: To evaluate the diagnostic effects of urine PCA-M (prostate cancer antigen -methylation) DNA level in patients with PSA from 4 to 20 ng/ml. Methods: We first explored the diagnostic value of PCAM (PRKY and TGIF2LY) based on prostate cancer samples from the TCGA database. Then ninety-five patients with PSA concentration of 4-20 ng/ml were collected as subjects. The level of urinary PCA-M DNA was detected by RT-PCR. The sensitivity and specificity of the diagnosis and the AUC were calculated and compared with f/t PSA, PSAD. Results: Bioinformatics analysis showed that the expression of PRKY in prostate cancer tissues was significantly higher than that in adjacent normal tissues, while the expression of TGIF2LY in normal prostate tissues was significantly higher than that in cancer tissues (P<0.001). The results of RT-PCR showed that the level of urinary PCA-M protein kinase PRKY in patients diagnosed with PCA (P<0.0001), while the level of urinary TGIF2LY in patients with PCA was on the contrary. The AUC value of urinary PRKY level was the highest compared with urinary TGIF2LY, f / tPSA and PSAD. Conclusions: PCA-M could be a biomarker for diagnosing patients with PSA from 4 to 20 ng/ml.